Who Optimizes SG&A Costs Better? Takeda Pharmaceutical Company Limited or Genmab A/S

Optimizing SG&A Costs: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Takeda Pharmaceutical Company Limited and Genmab A/S have showcased contrasting strategies in this domain. From 2014 to 2023, Takeda's SG&A expenses have consistently been higher, peaking at over 1 trillion in 2023, reflecting its expansive global operations. In contrast, Genmab's expenses, though rising, reached approximately 3.3 billion in the same year, indicating a more streamlined approach.

While Takeda's expenses grew by about 72% from 2014 to 2023, Genmab's surged by an impressive 4,000%, highlighting its rapid expansion and investment in growth. The data for 2024 is incomplete, but the trend suggests Takeda's continued dominance in expenditure. This analysis provides a fascinating insight into how these companies balance growth with cost management.